Home Contact Center Add this

Debiopharm Group™

A bridge between the discovery of new molecules and patient access

Debiopharm Group is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. The group in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

Besides drug development, Debiopharm has recently developed in-house skills in the field of companion diagnostics with a view to benefit from the key opportunities in personalized medicine.

Debiopharm Group independently funds the worldwide development of all of its products while providing expertise in all areas.

Societies

Rolland-Yves Mauvernay

Rolland-Yves Mauvernay

Honorary President & Founder, Debiopharm Group™

Dr Mauvernay completed his medical studies at the Faculty of Medicine and Pharmacy at the University of Strasbourg, France and later obtained his Ph.D. in Biology, Bacteriology and Pharmacy. In 1953, he established RIOM Laboratories, in Auvergne, France and purchased several pharmaceutical laboratories and various rare molecules. In 1973, he sold RIOM and in 1979, founded Debiopharm International SA, a biopharmaceutical development company which fully funds and develops innovative therapeutics. He later created Debiopharm Research & Manufacturing SA, specializing in the development of sustained-release advanced drug delivery systems and manufacturing. Today, Dr Mauvernay heads a group of 350 employees, supported by 500 external experts, who are responsible for research and development.

Thierry Mauvernay

Thierry Mauvernay

President & Delegate of the Board, Debiopharm Group™

Mr Mauvernay received his Master of Science in Economics in 1975. He then obtained a degree (MBA) from the 'Institut d'Administration des Entreprises’ and a DESS in Marketing (Master II Degree) in Clermont-Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he sold in 1998 but continued to manage until July 2001, when he joined Debiopharm International SA as Executive Vice President with direct responsibilities for the Finance and Administration Department. In 2006, Mr Mauvernay handed over his operational activities within Debiopharm International SA and has since been focusing on the administration, finance and strategy of Debiopharm Group. Since 2012, Mr Mauvernay is the Delegate of the Board of Debiopharm Group.

Against the background of the vision and of the mission of Debiopharm Group, the Strategy Committee helps the shareholders and leadership of the group to anticipate, identify and understand the upcoming trends as well as to adapt in a timely and realistic manner to the key features of tomorrow's pharmaceutical industry.

Thierry Mauvernay

President

Mr Mauvernay received his Master of Science in Economics in 1975. He then obtained a degree (MBA) from the 'Institut d'Administration des Entreprises’ and a DESS in Marketing (Master II Degree) in Clermont-Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he later sold but continued to manage until July 2001, when he joined Debiopharm SA as Executive Vice President with direct responsibilities for the Finance and Administration Department. In 2006, Mr Mauvernay handed over his operational activities within Debiopharm SA and has since been focusing on the administration, finance and strategy of Debiopharm Group. Since 2012 he is Delegate of the Board of Debiopharm Group.

Michele Antonnelli

Michele Antonelli

Member

Michele Antonelli has a master degree in Plant Biology from the University of Bari, Italy. He qualified the ENI’s (Italian National Oil Company) postgraduate programme in Biotechnology and Advanced Genetics at the Catholic University in Piacenza, Italy and at the Iowa State University Ames, Iowa, USA. From 1982 to 1992, he worked at Enichem, Italy as Research fellow and then as Head of Molecular and Cell Biology Unit. In 1992, he joined Serono in Geneva, Switzerland, where he held several senior managerial positions in Quality, Product and Process Development and Industrial Manufacturing in Biotechnology, and as Senior Vice President Biotech Manufacturing and Process Development. In 2008, Mr. Antonelli joined UCB as Executive Vice President Technical Operations & Quality Assurance. In 2012 he joined the European Commercial Operations team as Executive Vice President & Managing Director of UCB France. In November 2015 he joint Stallergenes SAS as the Executive Vice President, Head of International Operations. Since February 2016, Mr. Antonelli is the President of Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World.

Jean-Luc Belingard

Jean-Luc Belingard

Member

Mr. Belingard graduated from ‘Ecole des Hautes Etudes Commerciales (HEC) Paris (1971), and he holds a Master of Business Administration (MBA) from Cornell University, USA (1974). Since then, Mr. Belingard has held many management positions at Merck, Sharp and Dohme (Sales and Marketing Director, 1974-1981, Senior Director, Promotion Planning, 1981-1983), Roche France (“President du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMerieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010). In January 2011, Mr. Belingard was appointed Chairman and Chief Executive Officer of bioMérieux.

  

Bertrand Ducrey

General Secretary

Dr Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debio R.P. in 1995 as Pharmaceutical Project Manager. He spent two years at Debiopharm S.A. as Innovative Formulation Manager. In 2004, he returned to Debio R.P. S.A. to head the company as Chief Executive Officer. Since 2012, Dr Ducrey heads Debiopharm International SA as CEO.

Debiopharm Group™

Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
CH-1002 Lausanne
Switzerland

Tel. +41 (0)21 321 0111
Fax. +41 (0)21 321 0169